Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Geovax Labs Inc
Healthcare
P/NCAV
0.64x
Ticker
GOVX
Exchange
NASDAQ
Country
United States
Close
1.54 $
Mkt Cap
2.8M $
EV
-3.7M $
NCAV Burn Rate
82.0%
Current Ratio
2.24
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.1x
EV/FCF
0.1x
Dilution
99800.0% p.A
Total Net Income
-77.3M $
Cheapness
86.0%
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average